Using the structure of the epidermal growth factor receptor to fight cancer

Sep 13, 2010
The fly EGFR as a 'two-stage switch'. Its structure is shown in three stages, left to right. At left, no growth factors are bound (off). However, as one (middle) and two (right) growth factors bind (shown in magenta) it sends two different signals

(PhysOrg.com) -- The protein EGFR, which is the target of several cancer drugs, has a split personality at the cell surface, with two different classes (high-affinity and low-affinity), whose origins have been a mystery since the 1970s. Now, a new paper by Penn researchers published in Cell explains the difference between these two classes.

This video is not supported by your browser at this time.

Many types of tumors grow because of over-expression or a mutation of a protein called the (EGFR), normally regulated by a hormone-like peptide called the epidermal growth factor (EGF). Several , including , Erbitux, Iressa and Tarceva fight tumors by blocking EGFR and related receptors, notes Mark A. Lemmon, PhD, Professor and Chair of Biochemistry and Biophysics at the University of Pennsylvania School of Medicine.

EGFR has a split personality at the , with two different classes (high-affinity and low-affinity), whose origins have been a mystery since the 1970s. Now, a new paper from the Lemmon lab published recently in Cell explains the difference between these two classes by examining the structure of EGFR and its interactions with EGF.

The researchers took advantage of unique properties of the fruit fly equivalent of human EGFR as a window into the molecules' structures. They found that the EGF receptor acts like a two-stage switch.

“Two growth factors can bind to the receptor that signals across the membrane,” explains Lemmon. “With no receptors bound, the receptor is fully off. But, it looks as if there is a different type of signal if just one of the sites is filled as compared to when EGF is bound to both.” Interestingly, the insulin receptor is known to have similar properties.

Explore further: PDE-5 inhibitors tied to prostate cancer biochemical recurrence

add to favorites email to friend print save as pdf

Related Stories

Protein inhibits cancer cell growth

Dec 21, 2009

(PhysOrg.com) -- Researchers at the University of Toronto and Goethe University in Germany have discovered a protein that can inhibit the growth of cancer cells, providing crucial clues for the future development of new drugs ...

Scientists show how brain tumors outsmart drugs

Jan 19, 2010

Researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine and Moores UCSD Cancer Center have shown one way in which gliomas, a deadly type of brain tumor, ...

Recommended for you

Colon cancer rates rising among Americans under 50

4 hours ago

(HealthDay)—Although the overall rate of colon cancer has fallen in recent decades, new research suggests that over the last 20 years the disease has been increasing among young and early middle-aged American ...

The future of precision immunology

9 hours ago

In his State of the Union address, President Obama announced a new precision medicine initiative to work on finding a cure for cancer and other diseases. Howard L. Kaufman, a leading immunotherapy expert ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.